0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover440.28%IV-65.75%PremiumJan 17, 2025Expiry Date4.80Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9344Delta0.0151Gamma1.39Leverage Ratio-0.0217Theta0.0011Rho1.30Eff Leverage0.0025Vega
EyePoint Pharmaceuticals Stock Discussion
EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(5.2%),TCG Crossover Fund II, L.P.(5.2%), etc.
Positive
Positive interim DME trial data showing significant BCVA improvement of +8.9 letters
Successful completion of $161M equity financing
Extended cash runway into 2027
Initiation of Phase 3 LUGANO trial in wet AMD
Opening of new 40,000 sq ft cGMP manufacturing facility
Negative
Revenue declined 31% YoY to $10.5M from $15.2M
Net loss increased to $29.4M from $12.6M YoY
Operating expenses increased to $43.3M from $29.6M YoY
Cash position decreased to...
EyePoint Pharmaceuticals Inc - Commences $100 Million Public Offering
📊⚡️📊
Benzinga· 2 mins ago
EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(7.8%)
NEWS
EyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary Endpoint
Larger Image: tradingview.com...
$EyePoint Pharmaceuticals (EYPT.US)$
No comment yet